LSD for Health & Longevity

Created on 10/26/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

LSD, a laboratory-made psychedelic drug, is tested for persistent anxiety and depression; some take tiny repeated doses hoping for better mood and brain health. One or two supervised full-dose sessions brought lasting anxiety relief in repeated trials; depression evidence is partly mixed. Tiny doses showed no lasting benefit over placebo in healthy adults. Main risks are temporary: frightening experiences, nausea, raised blood pressure; lithium and illicit products add avoidable harm. (Full Review)

Protocol

Single-dose regimen (industry)
100 µg, once
Orally disintegrating tablet; monitored for at least 8 hours
Two-session assisted therapy (academic)
200 µg, two sessions
With preparatory and integration psychotherapy; or 100 µg then 200 µg for depression
Microdosing regimen
About 10 µg every third day
Trials used 5–20 µg every 4 days or 20 µg twice weekly
Time to effect
Reduced anxiety symptoms
From day 2
Lower for 12–16 weeks after one or two sessions
Reduced depressive symptoms
By week 1
Staying lower through week 12
Lasting well-being after a full-dose session
1 and 12 months
Higher well-being and life satisfaction after one 200 µg dose

Benefits

Contraindications
  • Personal or first-degree family history of psychotic disorders (schizophrenia, schizoaffective disorder) or bipolar I disorder
  • People taking lithium
  • Uncontrolled hypertension (130/80 mmHg or higher despite treatment), recent heart attack or stroke, or arrhythmia
  • Existing heart valve disease
  • Pregnancy and breastfeeding
  • Epilepsy or other seizure disorders
  • Current suicidal intent or unstable severe psychiatric illness
Key Interactions
  • SSRIs (such as fluoxetine, sertraline): weaker session effects
  • Paroxetine, a CYP2D6 inhibitor: raised LSD levels; no LSD dose change necessary
  • Tricyclic antidepressants (such as imipramine): risk of an overwhelming session
  • MAO inhibitors (such as phenelzine): blunted session effects
  • Ketanserin: shortened effects; planned or rescue option
  • MDMA: longer, more stimulating sessions
  • Antipsychotics (such as chlorpromazine, olanzapine): unpredictable session effects
  • Cannabis: more intense, sometimes anxious sessions
  • Alcohol: blunted perception of alcohol intoxication
  • 5-HTP and L-Tryptophan (supplements): possibly weaker session effects
  • Niacin (high-dose supplement): weaker session effects
Theoretical (inferred from mechanism)
  • Other serotonergic drugs (tramadol, triptans): serotonin syndrome
  • Stimulants and decongestants (amphetamine, pseudoephedrine): higher blood pressure and heart rate
  • Inhibitors of other LSD-metabolizing enzymes (fluvoxamine for CYP1A2): possibly higher exposure
  • Bupropion and other seizure-threshold-lowering drugs: possible seizure risk
  • St John's wort (supplement): serotonin toxicity or altered LSD levels
  • Yohimbine and high-dose caffeine supplements: more cardiovascular strain and anxiety
  • Sauna or strenuous heat exposure on session days: additive heat stress

Risk & Side Effects

  • High: Acute perceptual changes and psychological distress; nausea, headache and next-day fatigue
  • Medium: Rises in blood pressure, heart rate and body temperature
  • Low: Serious psychiatric reactions; hypomania and mania; flashbacks and persisting perceptual changes; injury from impaired judgment outside supervised settings; severe poisoning from very high or mistaken doses
  • Speculative: Heart valve damage with frequent repeated dosing

Monitoring

Marker Target Why
Blood pressure Below 120/80 mmHg Safety check: high values defer or stop dosing
Resting heart rate 60–100 beats/min Safety check: a fast heart rate defers dosing
CYP2D6 genotype No established target; record metabolizer status as a personal baseline Safety check: poor metabolizers warrant a lower dose
Echocardiogram (heart valve structure) No established target; track change from the individual's own baseline Safety check: new valve thickening stops repeated dosing
GAD-7 anxiety score 0–4, minimal anxiety Tracks anxiety response
PHQ-9 depression score 0–4, minimal depression Tracks depression response
Pregnancy test (urine hCG) Negative Safety check: positive result excludes dosing
Electrocardiogram (if cardiac risk factors exist) Not specified in the ER Baseline eligibility check

Cadence: Blood pressure and heart rate before dosing and hourly during full-dose sessions until effects resolve (about 6–12 hours); questionnaires at 1 week, 4 weeks and 12 weeks after a session, then every 3 months if further sessions are considered; for microdosing, questionnaires every 4 weeks and an echocardiogram every 6–12 months while dosing continues.

Qualitative Assessment

  • Anxiety, worry and rumination in daily life
  • Mood stability and interest in usual activities
  • Sleep quality on nights after sessions or microdoses
  • Sense of meaning and connectedness reported after sessions
  • Absence of persisting visual disturbances, paranoia or suicidal thoughts
  • Alcohol intake, where reduced drinking is a goal